A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
| 适应症 | Hepatocellular Carcinoma |
|---|---|
| 分期 | 2期 |
| 申办方 | David Hsieh |
| 状态 | 已完成 |
| 受试者人数 | 35 人 |
| 干预（药物） | Pembrolizumab, Bavituximab |
| 开始日期 | 2018年4月26日 |
| 完成日期 | 2023年4月21日 |
| 结果公布日 | 2024年7月17日 |
摘要
This is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC. Locally advanced or metastatic HCC is defined as disease that is not amenable to surgical and/or locoregional therapies. Subjects must not have received prior systemic therapy for advanced HCC in keeping with the first-line setting of this study.
Overall Response Rate
| Pembro + Bavi | 9 Participants |
|---|
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Treme — MedImmune LLC
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Live — National Cancer Institute (NCI)
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — CStone Pharmaceuticals
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver C — Edward Kim
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hep — AstraZeneca
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Di — National Cancer Institute (NCI)